The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Gilead Sciences; Janssen
Speakers' Bureau - Bristol-Myers Squibb; Celgene; Gilead Sciences; Roche
Phase 1 study of the safety and efficacy of INCB050465 combined with obinutuzumab and bendamustine for relapsed or refractory (R/R) follicular lymphoma (FL) (CITADEL-102).
 
Morton Coleman
Stock and Other Ownership Interests - Abbvie
Consulting or Advisory Role - Bayer; Gilead Sciences
Speakers' Bureau - Celgene; Gilead Sciences; Pharmacyclics
Research Funding - Celgene; Gilead Sciences; Merck; Millennium; Pharmacyclics; Roche
 
Antonio Salar
Consulting or Advisory Role - Incyte; Janssen; Roche; Sandoz
Speakers' Bureau - Mundipharma; Roche
 
Javier Munoz
No Relationships to Disclose
 
Natalie Galanina
No Relationships to Disclose
 
Thea Faivre
Employment - Incyte; Novartis
Stock and Other Ownership Interests - Incyte
Research Funding - Incyte; Novartis
Travel, Accommodations, Expenses - Incyte; Novartis
 
Pier Luigi Zinzani
No Relationships to Disclose